The biggest U.S. gasoline price surge in years is running out of steam just in time for the start of the summer driving season.Energyread more
Stocks rose on Friday, but notched weekly losses as investors worried the U.S.-China trade war is hurting economic growth.US Marketsread more
The combination of mounting recession fears, bets on a more cautious Fed and a regular uptick in market volatility could spell more losses.Marketsread more
The therapy, Zolgensma, is a one-time treatment for spinal muscular atrophy — a muscle-wasting disease and leading genetic cause of infant mortality, affecting 1 in every...Biotech and Pharmaceuticalsread more
SpaceX has raised just over $1 billion in financing since the beginning of the year.Investing in Spaceread more
An analyst for Ark Invest, which has a major investment in Tesla, says recent drastic price-target cuts by others on Wall Street are missing the big picture.Investingread more
A federal judge in California has blocked President Donald Trump from building sections of his long-sought border wall with money secured under his declaration of a national...Politicsread more
Former Foreign Minister Boris Johnson is seen as the bookmaker's favorite to succeed outgoing Prime Minister Theresa May.Europe Politicsread more
The race is underway to find a vaccine that can control African swine fever, a highly contagious and deadly viral infection ravaging China's hog population. There is currently...Agricultureread more
Apple bought Tueo Health, which was developing tech to help parents monitor asthma symptoms in children, using a mobile app and commercial breathing sensors.Technologyread more
Marijuana stocks ripped higher Thursday after the U.S. Drug Enforcement Administration classified a cannabidiol-based drug made by GW Pharmaceuticals in its least restrictive category, setting the stage for commercial launch.
Shares of the Cambridge, U.K.-based company rose 7 percent to an all-time high Thursday morning following the announcement. Peer Canada-based cannabis company Tilray rose 14.7 percent.
Epidiolex, the new GW Pharmaceuticals drug, uses cannabidiol, or CBD, to help with the treatment of seizures stemming from two rare and severe forms of epilepsy.
This announcement "renders the launch set-up fairly straightforward for GW into a market where there is significant unmet medical need and very high pent up awareness/demand," wrote Stifel analyst Paul Mattela.
"We continue to recommend the stock on the basis that we believe the Epidiolex launch can exceed first year expectations," the analyst added.
News of the mild DEA classification comes amid growing fascination on Wall Street over a handful of companies engaged in the cultivation and production of cannabis products for either medical or nonmedical purposes.
Other stocks in the limelight include pharmaceutical companies, including GW Pharmaceuticals, that produce and market drugs that use cannabinoids.
Tilray, for example, enthralled Wall Street last week after posting its best day ever following approval from the Drug Enforcement Administration to import pot to the United States for medical research.
Given the excitement around what appears to be an amenable DEA, Tilray shares have swung wildly over the last 10 days as investors are pinned between interest in a stake in the burgeoning industry and fears of an asset bubble.
Though both Aurora Cannabis and Canopy Growth — two other marijuana plays — traded lower Thursday, both stocks have endured similar frenzy over the last few weeks.